Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2017. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific equity transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Exercise of share options and subsequent sale of shares.
- Option Exercise: 2,249 shares exercised at a price of £14.88 per share.
- Share Sale: 2,220 shares sold at £15.8125 per share to cover option costs and tax liabilities.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategic direction compared to prior periods. It reports a routine compliance disclosure of a PDMR transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction involved Mr. R G Connor, President of Global Manufacturing & Supply, exercising options granted on February 20, 2007, under the GlaxoSmithKline Share Option Plan.
Investor Verification Points
- Verify the identity and role of the PDMR (Mr. R G Connor) in the company's latest annual report.
- Confirm the terms of the 2007 Share Option Plan referenced in the transaction.
- Check the London Stock Exchange (XLON) trading data for February 13, 2017, to validate the sale price of £15.8125.
- Note that this filing does not provide updated financial performance data for the company.